


PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/574,740
		Filing Date	05-18-2000
		Confirmation Number	9926
		First Named Inventor	M. South et al.
		Group Art Unit	<del>1644</del> 1624
		Examiner Name	TBA
Sheet 1 of 3	Attorney Docket No.	3202/1 (PHA 4160.1)	



**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
TNT	1 ✓	5,656,645		Tamura et al.	08-12-1997
I	2 ✓	5,658,930		Tamura et al.	08-19-1997
I	3 ✓	5,668,289		Sanderson et al.	09-16-1997
I	4 ✓	5,792,779		Sanderson et al.	08-11-1998
I	5 ✓	5,869,487		Coburn et al.	02-09-1999
TNT	6 ✓	6,037,356		Lu et al.	03-14-2000

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
TNT	7 ✓	EP	997 474	A1	Pfizer Inc.	05-03-2000	x
I	8 ✓	WO	96/18644	A1	Corvas International Inc.	06-20-1996	x
I	9 ✓	WO	97/01338	A1	Merck & Co., Inc.	01-16-1997	x
I	10 ✓	WO	97/30708	A1	Merck & Co., Inc.	08-28-1997	x
I	11 ✓	WO	97/46207	A2	Corvas International Inc.	12-11-1997	x
TNT	12 ✓	WO	98/09949	A1	Nippon KayKabushiki Kaisha (abstract)	03-12-1998	

Examiner Signature		Date Considered	9/5/02
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	09/574,740
			Filing Date	05-18-2000
			Confirmation Number	9926
			First Named Inventor	M. South et al.
			Group Art Unit	<del>1614</del> 1624
			Examiner Name	TBA
			Attorney Docket No.	3202/1 (PHA 4160.1)
Sheet	2	of	3	



TNT	13	✓	WO	98/16525	A1	Cor Therapeutics, Inc.	04-23-1998	x
	14	✓	WO	98/16547	A1	Cor Therapeutics, Inc.	04-23-1998	x
	15		WO	98/17274	A1	Merck & Co., Inc.	04-30-1998	x
	16	✓	WO	98/31670	A1	Merk & Co., Inc.	07-23-1998	x
	17	✓	WO	98/42342	A1	Merk & Co., Inc.	10-01-1998	x
	18	✓	WO	98/47876	A1	Akzo Nobel N.V.	10-29-1998	x
	19	✓	WO	98/50420	A1	Akzo Nobel N.V.	11-12-1998	x
	20	✓	WO	99/00126	A1	Eli Lilly and Company	01-07-1999	x
	21	✓	WO	99/11267	A1	Merck & Co., Inc.	03-11-1999	x
	22	✓	WO	00/18762	A1	Merck & Co., Inc.	04-06-2000	x
	23	✓	WO	00/26210	A1	Merck & Co., Inc.	05-11-2000	x
	24	✓	WO	00/26211	A1	Merck & Co., Inc.	05-11-2000	x
	25	✓	WO	00/32574	A1	Sanofi-Synthelabo (abstract)	06-08-2000	
TNT	26	✓	WO	00/39102	A1	Du Pont Pharmaceuticals Company	07-06-2000	x

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>6</sup>
TNT	27	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.						x

Examiner Signature		Date Considered	9/5/02
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A


INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/574,740
Filing Date	05-18-2000
Confirmation Number	9926
First Named Inventor	M. South et al.
Group Art Unit	<del>1614</del> 1624
Examiner Name	TBA
Attorney Docket No.	3202/1 (PHA 4160.1)

TMT	28 ✓	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	x
TMT	29 ✓	SANDERSON et al., "L-373,890, An Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12, pp. 1497-1500, 1997.	x

Examiner Signature		Date Considered	9/5/02
-----------------------	---	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

#5

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

PTO/SB/08A

**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**

Use as many sheets as necessary)

**Complete if Known**

Application Number	09/574,740
Filing Date	05-18-2000
Confirmation Number	9926
First Named Inventor	M. South et al.
Group Art Unit	<del>1614</del> 1624
Examiner Name	TBA
Attorney Docket No.	3202/1 (PHA 4160.1)


1

of

1

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
TNT	30.	WO	00/69826	A1	Monsanto Company	11-22-2000	x


Examiner Signature		Date Considered	1-25-02
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

#6

<b>PTO/SO-08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  		<b>Complete if Known</b>	
		Application Number	09/574,740
		Filing Date	05-18-2000
		Confirmation Number	9926
		First Named Inventor	M. South et al.
		Group Art Unit	<del>1814</del> 1624
Examiner Name	TBA		
Sheet <b>1</b>	of <b>2</b>	Attorney Docket No. 3202/1(PHA 4160.1)	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
TNT	31 ✓	5,441,960	B1	Bernstein et al.	08-15-1995
	32 ✓	5,861,380	B1	Gyorkos et al.	01-19-1999
	33 ✓	5,866,573	B1	Sanderson et al.	02-02-1999
	34 ✓	5,872,138	B1	Naylor-Olsen et al.	02-16-1999
TNT	35 ✓	6,011,158	B1	Tamura et al.	01-04-2000

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
TNT	36 ✓	EP	528 633	B1	Zeneca Limited	10-18-2000	x
	37 ✓	EP	826 671	A1	The Green Cross Corporation	03-04-1998	x
	38 ✓	EP	936 216	A1	Nippon Kayaku Kabushiki Kaisha	08-18-1999	x
	39 ✓	EP	940 400	A1	Yoshitomi Pharmaceutical Industries, Ltd.	09-08-1999	x
TNT	40 ✓	WO	93/21214	A1	Zeneca Limited	10-28-1993	x

Examiner Signature		Date Considered	9/5/02
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/574,740
Filing Date	05-18-2000
Confirmation Number	9926
First Named Inventor	M. South et al.
Group Art Unit	<del>4614</del> 1624
Examiner Name	TBA
Attorney Docket No.	3202/1(PHA 4160.1)

Sheet 2 of 2

TNT	41	✓	WO	96/33974	A1	The Green Cross Corporation (abstract)	10-31-1996	
	42	✓	WO	96/39380	A1	3-Dimensional Pharmaceuticals, Inc.	12-12-1996	x
	43	✓	WO	96/40100	A1	3-Dimensional Pharmaceuticals, Inc.	12-19-1996	x
	44	✓	WO	97/40024	A1	Merck & Co., Inc.	10-30-1997	x
	45	✓	WO	98/08840	A1	Merck & Co., Inc.	03-5-1998	x
	46	✓	WO	98/10763	A1	Merck & Co., Inc.	03-19-1998	x
	47	✓	WO	99/00121	A1	Eli Lilly and Company	01-07-1999	x
	48	✓	WO	99/00128	A1	Eli Lilly and Company	01-07-1999	x
	49	✓	WO	99/26920	A1	Corvas International, Inc.	06-03-1999	x
	50	✓	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	x
	51	✓	WO	99/36426	A1	Warner-Lambert Company	07-22-1999	x
	52	✓	WO	99/59591	A1	Merck & Co., Inc.	11-25-1999	x
	53	✓	WO	99/61442	A1	Merck & Co., Inc.	12-02-1999	x
	54	✓	WO	99/62538	A1	Cortech Inc.	12-09-1999	x
	55	✓	WO	99/64446	A1	3-Dimensional Pharmaceuticals, Inc.	12-16-1999	x
	56	✓	WO	00/69832	A1	Monsanto Company	11-23-2000	x
TNT	57	✓	WO	00/69833	A1	Monsanto Company	11-23-2000	x

Examiner  
Signature

Date  
Considered

9/5/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

#10


PTO/SB/08A		Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/574,740		
		Filing Date	05-18-2000		
		Confirmation Number	9926		
		First Named Inventor	M. South et al.		
		Group Art Unit	1614		
		Examiner Name	<del>IDA</del> T. TRUONG		
Sheet	1	of	1	Attorney Docket No.	3202/1(PHA 4160.1)

RECEIVED

MAR 9 8 2002

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
TNT	58	DARVAS, F. et al., "Investigation of the common mechanism of action of antibacterial compounds containing gamma-pyridone-beta-carboxylic acid structure by principal component", Retrieved from STN Database accession no. 93:1350, XP002182132, abstract, Arzneim. -Forsch. (1979), 22(9), 1334-9.	
TNT	59	PATEL et al., "Directed aminomethylation of 3-Hydroxy-2(1H)pyridinones and -3hydroxy-4(1H)-pyridinones: Synthesis of iso-deferiprone." Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 52, No. 5, 1996, XP004104485.	
TNT	60	TRECOURT, et al., "First synthesis of (+/-) harizianopyridone by metalation of polysubstituted O-pyridylcarbamates." Retrieved from STN Database accession no. 123:256397, XP002182410 abstract, J. Heterocycl. Chem (1995), 32(4), 1117-4.	

Examiner Signature		Date Considered	8/14/02
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

412

RECEIVED

PTO/SB/08A  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/574,740		
		Filing Date	May 18, 2000		
		Confirmation Number	9926		
		First Named Inventor	M. South		
		Group Art Unit			
Examiner Name					
Sheet	1	of	1	Attorney Docket No.	3202/1 (PHA 4160.1)



TECH CENTER 1600/2900  
JUL 18 2002

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>
TNT	61	RAUCH, et al., Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences, Annals of Internal Medicine, 2001, pp. 224-233, Vol. 134 - No. 3 .					
TNT	62	VAN AKEN, et al., Anticoagulation: The Present and Future, Clin. Appl. Thrombosis/Hemostasis, 2001, pp. 195-204, Vol. 7 - No. 3 ,					

Examiner Signature		Date Considered	8/14/02
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.